Quitting combustible cigarettes remains one of the highest-impact health decisions an adult smoker can make, yet cessation rates with traditional pharmacotherapy remain stubbornly low. A structured clinical framework for discussing nicotine e-cigarettes with patients arrives at a moment when clinicians are increasingly fielding questions about vaping as a quit-smoking strategy — and often lack clear, evidence-based guidance on how to respond.
Published in JAMA, this Special Communication synthesizes the current evidence base on electronic nicotine delivery systems as cessation aids and translates it into actionable clinical recommendations. The authors address how clinicians should frame conversations with adult patients who currently smoke, acknowledging that e-cigarettes occupy a contested middle ground: meaningfully less harmful than combustible tobacco on several toxicological measures, yet not without their own risk profile. The guidance appears designed to help practitioners navigate the tension between harm reduction pragmatism and the absence of long-term vaping safety data.
This communication lands within a broader and still-evolving research landscape. Randomized controlled trials — most notably the 2019 UK-based trial published in the New England Journal of Medicine — have shown nicotine e-cigarettes to outperform traditional nicotine replacement therapy for short-term cessation, though one-year abstinence rates remain modest. The challenge for clinicians has always been that regulatory ambiguity and institutional caution have left a guidance vacuum. JAMA-level recommendations from a credible clinical body carry significant weight in shaping practice norms. Key limitations to hold in mind: most cessation trial data involve relatively short follow-up windows, dual use of e-cigarettes and combustibles is common and may undermine net health benefit, and adolescent uptake risks mean population-level messaging requires careful calibration. For adult smokers who have failed conventional cessation methods, this framework may represent a meaningful clinical inflection point, though it is unlikely to settle the broader public health debate.